The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma

Glioblastoma (GBM) is the most common malignant primary brain tumor and confers a dismal prognosis. With only two FDA-approved therapeutics showing modest survival gains since 2005, there is a great need for the development of other disease-targeted therapies. Due, in part, to the profound immunosup...

Descripción completa

Detalles Bibliográficos
Autores principales: Neth, Bryan J., Webb, Mason J., Parney, Ian F., Sener, Ugur T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141140/
https://www.ncbi.nlm.nih.gov/pubmed/37111620
http://dx.doi.org/10.3390/pharmaceutics15041134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141140/
https://www.ncbi.nlm.nih.gov/pubmed/37111620
http://dx.doi.org/10.3390/pharmaceutics15041134

Ejemplares similares